α‑klotho and anemia in patients with chronic kidney disease patients: A new perspective (Review)
Published online on: October 11, 2017
Copyright: © Xu et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: PDF 0 views
| HTML 0 views
Normocytic normochromic anemia is a common complication of chronic kidney disease (CKD) and is associated with numerous adverse consequences. Certain symptoms previously attributed to CKD are now known to be a consequence of anemia. Anemia contributes to an increased cardiac output, and the development of left ventricular hypertrophy, angina and congestive heart failure, leading to high morbidity and mortality in patients with CKD. The multifunctional α‑klotho (KL) protein, which is predominantly expressed in the kidneys, is associated with the occurrence of anemia in patients with CKD. The present review presents current evidence on the potential role of α‑KL in renal anemia. Low expression of α‑KL appears to improve anemia in patients with CKD, and has been hypothesized to be a compensatory mechanism to attenuate the effects of anemia in patients with CKD. Further understanding of the role of α‑KL in renal anemia may offer novel insights into the treatment of patients with CKD complicated with anemia.